- Home
- AARD vs NECB Comparison
AARD vs NECB Comparison
Compare AARD & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- NECB
- Stock Information
- Founded
- AARD 2017
- NECB 1934
- Country
- AARD United States
- NECB United States
- Employees
- AARD N/A
- NECB N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- NECB Savings Institutions
- Sector
- AARD Health Care
- NECB Finance
- Exchange
- AARD Nasdaq
- NECB Nasdaq
- Market Cap
- AARD 277.9M
- NECB 282.4M
- IPO Year
- AARD 2025
- NECB N/A
- Fundamental
- Price
- AARD $11.22
- NECB $20.99
- Analyst Decision
- AARD Strong Buy
- NECB
- Analyst Count
- AARD 7
- NECB 0
- Target Price
- AARD $31.43
- NECB N/A
- AVG Volume (30 Days)
- AARD 151.9K
- NECB 50.1K
- Earning Date
- AARD 11-14-2025
- NECB 10-23-2025
- Dividend Yield
- AARD N/A
- NECB 3.82%
- EPS Growth
- AARD N/A
- NECB N/A
- EPS
- AARD N/A
- NECB 3.21
- Revenue
- AARD N/A
- NECB $102,569,000.00
- Revenue This Year
- AARD N/A
- NECB $1.90
- Revenue Next Year
- AARD N/A
- NECB $6.93
- P/E Ratio
- AARD N/A
- NECB $6.52
- Revenue Growth
- AARD N/A
- NECB N/A
- 52 Week Low
- AARD $4.88
- NECB $19.41
- 52 Week High
- AARD $19.58
- NECB $31.72
- Technical
- Relative Strength Index (RSI)
- AARD 39.08
- NECB 54.73
- Support Level
- AARD $10.65
- NECB $20.00
- Resistance Level
- AARD $17.94
- NECB $20.63
- Average True Range (ATR)
- AARD 0.95
- NECB 0.57
- MACD
- AARD -0.64
- NECB 0.13
- Stochastic Oscillator
- AARD 7.82
- NECB 90.29
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.